Compare Hims and Hers Health Inc (HIMS) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Phillips 66 — how do they compare? Hims and Hers Health Inc trades at $30.88 (market cap $6.55B), while Phillips 66 trades at $278 (market cap $112.36B). The key difference: Phillips 66 is far larger — about 17.2× Hims and Hers Health Inc's market cap, and Phillips 66 pays a 1.8% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Phillips 66 for 62 Days on average.
| HIMS | PSX | |
|---|---|---|
Market Cap | $6.55B | $112.36B |
Volume | 14,842,814 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $62.76 | $281.60 |
52-Week Low | $14.52 | $126.76 |
Typical Hold Time | 21 Days | 62 Days |
Enterprise Value | $7.25B | $128.83B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.
The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.
Phillips 66 (PSX) trades at $283.31, up 4.3% with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 16.07, ROE of 24.02%, and consistent earnings beats in recent quarters. Recent news highlights structural refining advantages and AI implementation for operational efficiency, while analyst consensus remains positive with 54% buy ratings.
PSX presents a compelling investment case with strong profitability metrics and positive earnings momentum, though investors face risks from volatile energy markets and potential policy changes affecting diesel exports. The current price sits near consensus targets, suggesting balanced near-term upside potential with structural refining strengths supporting long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
